Trial · NCT03296527
Outcomes61
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 40 of 61
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Circulating Concentrations of Estradiol | On stimulation Day 6 | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | pmol/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Estradiol | End-of-stimulation (up to 20 stimulation days) | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | pmol/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Progesterone | On stimulation Day 6 | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | nmol/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Progesterone | End-of-stimulation (up to 20 stimulation days) | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | nmol/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Inhibin A | On stimulation Day 6 | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | ng/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Inhibin A | End-of-stimulation (up to 20 stimulation days) | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | ng/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Inhibin B | On stimulation Day 6 | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | ng/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Inhibin B | End-of-stimulation (up to 20 stimulation days) | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | ng/L | MEDIAN |
| SECONDARY | Circulating Concentrations of Follicle-stimulating Hormone (FSH) | On stimulation Day 6 | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | IU/L | MEDIAN |
| SECONDARY | Circulating Concentrations of FSH | End-of-stimulation (up to 20 stimulation days) | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | IU/L | MEDIAN |
| SECONDARY | Circulating Concentrations of FSH | At oocyte retrieval | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | IU/L | MEDIAN |
| SECONDARY | Total Gonadotropin Dose | Up to 20 stimulation days | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | microgram of dose | MEAN |
| SECONDARY | Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments | Up to 20 stimulation days | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | percentage of participants | NUMBER |
| SECONDARY | Number of Stimulation Days | Up to 20 stimulation days | The FAS was defined as all randomized and exposed participants. Participants were analyzed according to randomized treatment. | days | MEAN |
| SECONDARY | Number of Participants With Adverse Events | From screening up to end-of-trial (up to approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Intensity of Adverse Events | From screening up to end-of-trial (up to approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants were analyzed according to actual treatment received. | percentage of participants | NUMBER |
| SECONDARY | Changes From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase | From screening up to end-of-trial (up to approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | IU/L | MEAN |
| SECONDARY | Change From Baseline in Clinical Chemistry Parameters: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | mmol/L | MEAN |
| SECONDARY | Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | g/L | MEAN |
| SECONDARY | Change From Baseline in Clinical Chemistry Parameter: Lactate Dehydrogenase | From screening up to end-of-trial (approximately 5.5 months) | The safety analysis set was defined as all randomized and exposed participants. Participants analyzed for this endpoint represent participants who were evaluable for this outcome measure. | U/L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296527/outcomes?page=2